Core Viewpoint - Zhejiang Sitaili Pharmaceutical Co., Ltd. is preparing for its shareholder meeting scheduled for May 22, 2025, focusing on maintaining shareholder rights and ensuring orderly proceedings during the meeting [1][2]. Meeting Arrangements - The meeting will be held on May 22, 2025, at 14:30, with online voting available from 9:15 to 11:30 and 13:00 to 15:00 on the same day [3]. - The venue for the meeting is located at No. 9, Fengxi West Road, Modern Industrial Gathering Area, Xianju County, Zhejiang Province [3]. Shareholder Rights and Meeting Conduct - Shareholders have the right to speak, inquire, and vote, but must apply to the meeting's organizing committee to do so [2]. - The voting will be conducted via a named ballot, with each share granting one vote, and any improperly filled ballots will be considered as abstentions [2][3]. Board of Directors and Governance - The fifth board of directors consists of 7 members, including 3 independent directors, and has held 8 meetings during the reporting period to discuss various corporate matters [6]. - The board has focused on maintaining good governance and protecting shareholder interests through active discussions and independent opinions [6]. Financial Performance Overview - The company reported a steady growth in operating performance for 2024, with total assets reaching approximately 6.05 billion yuan, an increase of 9.59% compared to the previous year [15]. - The financial report indicates a decrease in cash and cash equivalents by 14.47% and a decline in accounts receivable by 10.76% [14][15]. Future Outlook - The company anticipates challenges in 2025 due to external factors such as safety and environmental risks, as well as increased competition in the industry [9]. - The board will closely monitor changes in external policies and economic conditions to provide strategic recommendations for sustainable development [9].

Group 1 - The company has decided to postpone the completion date of its fundraising project from December 31, 2024, to December 31, 2025, to ensure the safe and effective use of raised funds and to maintain the interests of the company and its shareholders [7] - In 2024, the company achieved operating revenue of 87,198.12 million, representing a year-on-year increase of 22.27%, while the net profit attributable to shareholders decreased by 19.87% to 6,299.97 million [9] - The decline in net profit despite revenue growth is attributed to the expansion of the company's operational scale and increased expenses under its self-brand development strategy [9] Group 2 - The company conducted foreign exchange trading for hedging purposes on March 19, 2024, and August 5, 2024, but failed to timely fulfill the corresponding review procedures and information disclosure obligations [9] - The company has been advised to actively implement effective measures to reduce costs and increase efficiency in future business development to enhance operational performance [9]

Group 1 - The company held the 10th meeting of the 5th Supervisory Board on April 22, 2025, where all members were present and the meeting complied with relevant regulations [10] - The Supervisory Board approved the 2024 annual report, confirming that the report accurately reflects the company's situation without any false statements or omissions [11] - The company reported a net profit of 97,090,017.90 yuan for 2024, but has negative retained earnings of -1,263,784,051.41 yuan as of December 31, 2024, leading to a proposal not to distribute dividends [35][33] Group 2 - The company plans to use up to 700 million yuan of idle funds for low-risk financial products to improve fund efficiency [51][52] - The company will conduct foreign exchange hedging activities with a total limit of up to 8 million USD to mitigate currency risk [61][63] - The company has identified and will account for credit and asset impairment losses totaling 80,332,536.25 yuan and 12,186,238.26 yuan respectively [71][72] Group 3 - The company discovered non-operational fund occupation by its controlling shareholder, totaling 9.5598 million yuan, which has been fully repaid [75][76] - The company has implemented corrective measures to strengthen internal controls and prevent future occurrences of fund occupation [78]

Group 1 - The company plans to apply for a bank credit limit of up to 1 billion RMB for 2025, which can be used for various financing needs including working capital loans and project development loans [3][4][49] - The credit limit is subject to bank approval and can be reused within a maximum term of five years [3][4] - The actual financing amount will depend on the company's operational needs and will be determined based on actual transactions with the bank [4] Group 2 - The company intends to use idle self-owned funds for cash management, with a total investment limit of up to 1 billion RMB in low-risk financial products [7][8][10] - The investment aims to improve the efficiency and returns of idle funds while ensuring the company's normal operations are not affected [9][15] - The investment period will last from the approval date by the shareholders' meeting until the next annual shareholders' meeting in 2025 [11] Group 3 - The company has authorized the general manager to approve specific financing matters and amounts within the approved credit limit to enhance operational efficiency [4][52] - The board of directors has passed several resolutions, including the proposal for the use of idle funds and the application for bank credit, which will be submitted for shareholder approval [5][6][12][13]

证券代码：002881 证券简称：美格智能 公告编号：2025-011 美格智能技术股份有限公司 第四届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 美格智能技术股份有限公司（以下简称"公司"）监事会于 2025 年 2 月 24 日以书面方式发出了公司第四届监事会第四次会议的通知。本次会议于 2025 年 2 月 28 日在深圳市福田区深南大道 1006 号深圳国际创新中心 B 座 32 楼公司会议室 以现场结合通讯表决方式召开。会议应参加表决监事 3 人，实际参加表决监事 3 人，会议由监事会主席宁欢先生主持。本次会议的通知、召集和召开符合《中华 人民共和国公司法》等法律、行政法规、规范性文件和《公司章程》的有关规定， 合法有效。 1、审议通过了《关于 2025 年度贷款计划及贷款授权的议案》。 为更好的支持公司业务拓展，同时也为了保证公司银行授信的延续性，公司 及控股子公司拟在 2025 年度向金融机构申请不超过人民币 30 亿元的综合授信额 度，授权公司管理层在上述额度内代表公司对外签署相关文件。 表 ...